Stock Detail
CELL THERAPEUTICS INC
Sector: Drug Manufacturers Other
Latest Quote @ Tue May 5 04:29:16 (15 min delayed)
| $1.12 |
$1.23 |
$1.22 |
+0.06 |
5.17% |
1.18M |
Last Day's Data
| $1.22 |
$1.22 |
$0.06 |
5.17% |
0.00 |
$1.16 |
| $1.15 |
$1.14 |
1.00 |
133.80M |
626,656.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 1.27 |
1.24 |
1.19 |
1.16 |
1.11 |
Stock Profile
Cell Therapeutics, Inc. engages in the discovery, development, acquisition, and commercialization of drugs for the treatment of cancer. The company markets TRISENOX (arsenic trioxide) for the treatment of relapsed or refractory acute promyelocytic leukemia. Cell Therapeutics develops XYOTAX, paclitaxel linked to a polyglutamate polymer, which is used for the potential treatment of nonsmall cell lung cancer and ovarian cancer. It uses a biodegradable protein polymer to deliver the chemotherapy paclitaxel principally to tumor tissue. The company develops pixantrone, which is in clinical trials for the potential treatment of relapsed aggressive nonhodgkin's lymphoma. It operates primarily in the United States and Italy. The company was co-founded by James A. Bianco, Louis A. Bianco, and Jack W. Singer in 1991. Cell Therapeutics is headquartered in Seattle, Washington.
